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Morie A. Gertz,1 Irene Ghobrial,2 Jean Luc-Harousseau3The understanding of the pathogenesis of multiple myeloma has undergone a major transformation over the
past eight years. New insights into the microenvironment of the plasma cell as well as elucidation of signaling
pathways that prevent plasma cell apoptosis are leading to rapid new drug development. The introduction of
novel agents has led to a significant increase in survival. Combinations of novel agents are expected to pro-
vide higher complete response rate with anticipated prolongation of relapse free and overall survival. Autol-
ogous and allogeneic stem cell transplantation remains an integral part of therapy further improving the
outcomes following induction with novel agents.
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Multiple myeloma (MM) is the second most prev-
alent hematologic malignancy, with an incidence of 4.3
per 100,000 in the general population, and a median
survival of 3 to 5 years [1]. Significant advances in un-
derstanding the underlying genetic and epigenetic
alterations that lead to tumor initiation and progres-
sion have been elucidated recently [2]. These have
lead to the constitutive activation of many signaling
pathways that induce proliferation and resistance to
therapy. In addition, the bone marrow (BM) microen-
vironment plays a crucial role in the development of
resistance and progression of this disease [3]. These
molecular events are triggered either directly, through
cell adhesion molecule–mediated interactions of MM
cells with BM stromal cells (BMSCs) and endothelial
cells, osteoclasts, and osteoblasts, or indirectly, by
growth factors released by these cells. These bidirec-
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6/j.bbmt.2008.10.006cal sequelae, including enhanced osteoclastogenesis,
resulting in osteolytic lesions, as well as MM cell resis-
tance to conventional chemotherapeutic agents, even
in the absence of genetic lesions that confer constitu-
tive resistance. Recently developed agents target the
malignant cells and their microenvironment and are
leading to improved survival in these patients [4].
MM cells are characterized by genetic instability
with several chromosomal abnormalities. Transloca-
tions involving the immunoglobulin heavy-chain
(IgH) locus are important factors in pathogenesis in
50% of patients. In the 50% patients without IgH
translocations, hyperdiploidy is the hallmark of the
disease. Several important genetic markers are associ-
ated with decreased survival, including chromosome
13 monosomy, hypodiploidy, and others [5,6]. Inte-
grated analysis of high-density oligonucleotide array
(aCGH) and gene expression profiling data have led
to the discovery of many new abnormalities in these
patients, including mutations in the nuclear factor
kappa-beta (NF-kB) pathway in approximately 20%
of patients [2]. These genetic alterations lead to consti-
tutive activation of signaling proteins; for example,
MM cells with t(14;16) translocations overexpress the
transcription factor c-maf, which transactivates the cy-
clin D2 promoter, thereby enhancing MM cell prolif-
eration as well as enhancing b7-integrin expression
and tumor cell adhesion to BMSCs [7]. Hyperdiploidy
renders MM cells uniquely dependent on the BM mi-
croenvironment, which induces cyclin D1 overexpres-
sion despite the absence of Ig translocations [8].
These genetic alterations, as well as external
stimulation from the microenvironment, lead to
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ing cascades, including phosphatidylinositol-3 kinase
(PI3K)/Akt, NF-kkB, Ras/Raf/mitogen-activated pro-
tein kinase (MAPK) kinase (MEK)/extracellular
signal–related kinase (ERK), and Janus kinase (JAK)
2/signal transducers and activators of transcription
(STAT) 3 [3]. Downstream sequelae of activation of
these pathways lead to cytoplasmic sequestration of
many transcription factors (eg, FKFR), up-regulation
of cell cycle–regulating proteins (eg, cyclin D) and
antiapoptotic proteins (eg, Bcl-2, Bcl-xL, Mcl-1), and
increased activity of telomerase. Interactions between
these pathways lead to proliferation, survival, resis-
tance to therapy as well as dynamic migration, and ad-
hesion of MM cells to the BM milieu [6].
The BMmicroenvironment consists of a landscape
of cells, including hematopoietic stem cells, BMSCs,
BM endothelial cells, fibroblasts, osteoclasts, and oste-
oblasts, as well as the extracellular matrix proteins,
such as laminin, collagen, fibronectin, and osteopontin
[9]. It is well established that the BM microenviron-
ment plays a pivotal pathophysiologic role in MM.
The interactions of MM cells with the microenviron-
ment are due to direct cell–cell interactions or through
soluble factors secreted by theMM cells or the BMmi-
lieu cells. Direct adhesion of MM cells to endothelial
cells, BMSCs, and extracellular matrix proteins, such
as fibronectin, lead to enhanced survival and prolifera-
tion and confer resistance to drug-induced apoptosis.
Conversely, the presence of MM cells and their prolif-
eration in the BM milieu lead to enhanced angiogene-
sis, increased activity of osteoclasts, and inhibition of
osteoblasts, resulting in the development of lytic le-
sions and enhanced morbidity in these patients [9].
Similarly, growth factors secreted by the interaction
of MM cells with BM microenvironment cells induce
pleiotropic effects, such as stimulating osteoclastogen-
esis (eg, interleukin [IL]-6, IL-1, vascular endothelial
growth factor, stromal-derived cell factor 1a, macro-
phage inflammatory protein 1a) or modulating
adhesion molecule profiles on MM cells and BMSCs
(eg, tumor necrosis factor a). Importantly, this
growth factor circuit between MM cells and BMSCs
in the BM milieu promotes MM cell growth, survival,
and migration, contributing to both MM progression
and resistance to conventional therapies. The dynamic
trafficking of MM cells (homing to the BM and egress
from the BM to new sites) leads to rapid dissemination
ofMM into multiple focal lesions in the BM. This pro-
cess is highly regulated by chemokines, adhesion mol-
ecules, and selectins, which are secreted and regulated
by theMM cells and the BMmicroenvironmental cells
[10].
Advances in understanding the underlying molec-
ular alterations in MM and the BMmicroenvironment
have led to a rapid development of clinical trials using
novel targeted therapeutic agents. The treatment ofMM has evolved from the era of melphalan and
prednisone in the 1960s through high-dose chemo-
therapy and stem cell transplantation in the 1990s
and to the introduction of novel targeted therapeutic
agents in the last decade [1,4]. Within the last 4 years,
3 novel agents—bortezomib, thalidomide, and lenali-
domide—have received Food and Drug Administra-
tion (FDA) approval for use in treating MM, leading
to a paradigm shift in the treatment algorithm of
MM [4]. These agents have become integral in the
therapy for MM in both induction therapy for newly
diagnosed patients and in the salvage setting for pa-
tients with relapsed and refractory disease. The success
of targeted therapy in MM has led to the development
and testing of more than 30 new therapeutic agents in
the preclinical or in early phase I and II clinical setting
[4]. Some of these agents target specific signaling path-
ways, including heat shock protein inhibitors (17-
AAG, KOS-953, IPI-504), protein kinase C inhibitors
(eg, enzastaurin), PI3K/Akt inhibitors (BEZ235, peri-
fosine, CCI-779, RAD001, AP23573), MEK/ERK
inhibitors (AZD-6244, tipifarnib), p38MAPK inhibi-
tors (SCIO-469), and SAPK/JNK inhibitors (aplidin).
Other inhibitors target specificmechanisms of cell sur-
vival and proliferation, including proteasome activity
inhibitors (NPI-0052, PR-171), histone deacetylase
inhibitors (SAHA, LBH-589), and DNA synthesis in-
hibitors (AVN944). Finally, other novel agents target
cell surface receptors, including anti-CD40 antibodies
(SGN40), IGF-1R inhibitors (NVP-ADW742, CP-
51871), and FGFR3 inhibitors (TKI-258) [4]. These
agents target specific signaling pathways in MM cells
as well as in the BM microenvironment, leading to in-
creased responses and prolonged survival and making
MM a model disease for the development of targeted
therapeutic agents [4].STANDARD THERAPY
In the United States, 19,900 cases of MM are diag-
nosed annually, leading to more than 10,790 deaths.
The median survival is 4 to 5 years. MM is the second
most common hematologic malignancy and is incur-
able with current approaches. The median age at pre-
sentation is 66 years [11]. Treatment of MM should be
driven by the patient’s biological risk and suitability for
high-dose therapy. The most common classification of
risk is cytogenetically based, in which patients who
show FISH del(17p), t(4;14), t(14;16), metaphase cyto-
genetic deletion 13, or hypodiploidy are considered
high-risk patients; this accounts for approximately
25% of newly diagnosed cases of MM. All other pa-
tients, including those with metaphase hyperdiploid
cytogenetics, t(11;14), or t(6;14), are considered to be
at standard risk [12]. In most European nations, all pa-
tients up to age 65 are considered eligible for stem cell
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is deemed able to withstand the rigors of high-dose
therapy with a mortality risk of\ 2% is considered a
viable candidate.Patientswhoarenot considered candi-
dates for stem cell transplantation receive a melphalan-
containing regimen,which is not be suitable for patients
in whom high-dose therapy is being considered.
A prospective randomized phase III study of borte-
zomib-thalidomide-dexamethasone versus thalido-
mide-dexamethasone in newly diagnosed MM cases
has been reported [13]. Patients received thalidomide
200 mg daily; bortezomib on a standard schedule of
1.3 mg/m2 on days 1, 4, 8, and 11; and dexamethasone
40 mg on the day of and the day after bortezomib ther-
apy. All patients were under age 65. A total of 351 pa-
tients enrolled, of whom 256 were evaluable. At the
completion of induction therapy, a complete response
or near-complete response was seen in 36% of the bor-
tezomib thalidomide dexamethasone (VTD) patients
versus 9% in the thalidomide dexamethasone (TD) pa-
tients. Very good partial remission (VGPR) or better
was seen in 60% of the VTD patients, compared with
27% of the TDpatients (P5 .001). Peripheral neurop-
athy was significantly higher (7%) in the bortezomib-
containing group. Skin rashes were seen in 6.5%.
The incidence of deep venous thrombosis (DVT) was
only half in the bortezomib-containing group; DVT
prophylaxis included aspirin, warfarin, or enoxaparin
in a randomized scheme. After stem cell transplanta-
tion, the rate of complete remission (CR) or near CR
was 57% in the VTDgroup and 28% in theTD group,
and VGPR or better was seen in 77% of the VTD
group and in 54% of the TD group.
A phase III trial of lenalidomide and high-dose
dexamethasone at a standard dose of 40 mg on days 1
to 4, 9 to 12, and 17 to 21 was compared with dexa-
methasone at a dosing schedule of 40 mg 1 day per
week [14]. At 2 years, overall survival (OS) was signif-
icantly higher in the low-dose dexamethasone group
(87% vs 75%; P5 .006). The difference inOS between
the 2 groups was attributed to the higher early mortal-
ity in patients over age 65 in the high-dose dexameth-
asone group. Stem cell transplantation was performed
in 29% of the patients in the high-dose dexamethasone
group and in 31% of the patients in the low-dose dexa-
methasone group. In the patients who continued on
primary therapy beyond 4 induction cycles, 1-year
OS was 96% in the high-dose group and 99% in the
low-dose group, and 2-year OS was 80% in the high-
dose group and 91% in the low-dose group. These
findings indicate that reduced dexamethasone inten-
sity resulted in superior OS. The early death rate was
5% in the high-dose group versus 0.5% in the low-
dose group. The median progression-free survival
(PFS) was 19.3 months in the high-dose group versus
22 months in the low-dose group.Higher response rates should not be equated with
a superior OS. In a long-term follow-up of patients re-
ceiving melphalan-prednisone-thalidomide (MPT)
and those receiving melphalan-prednisone (MP), the
median PFS was 21.8 months for the former and
14.5 months for the latter, but the OS did not differ
significantly between the 2 groups (45 months vs
47.6 months). The use of thalidomide or bortezomib
as salvage therapy significantly improved survival after
first progression in the MP group but not in the MPT
group. The availability of novel agents for salvage
therapy can compensate for the lower response rate
and response duration when they are omitted from
the initial therapy [15].
The Southwest Oncology Group randomized 200
patients to both lenalidomide and high-dose dexa-
methasone and to dexamethasone alone. The rate of
CR was 22% in the lenalidomide-dexamethasone
arm and 4% in the dexamethasone arm, with
corresponding 12-month PFS of 77% and 55%. The
additive benefit of lenalidomide in relapsed disease
was reported by pooling the data from 2 studies cover-
ing 700 patients, demonstrating CR rates of 24% for
lenalidomide-dexamethasone versus 3.4% for dexa-
methasone and a superior OS in those patients who
had received more than 1 regimen before study entry
[16]. At amedian of 35months from the start of salvage
therapy, 58% of the patients were alive. The median
survival in the dexamethasone arm was 31 months
(P 5 .02). This benefit of lenalidomide was seen
whether or not the patient underwent previous stem
cell transplantation. Lenalidomide may affect stem
cell mobilization, and thus earlier collection may
need to be considered [17].
For patients not eligible for transplantation, a mel-
phalan-based regimen combined with a novel agent
(bortezomib, thalidomide, or lenalidomide) is the cur-
rent treatment of choice. The VISTA trial used 4 cy-
cles of bortezomib on days 1, 4, 8, 11, 22, 25, 29, and
32 every 42 days, followed by 5 cycles of bortezomib
on days 1, 8, 22, and 29 every 42 days, combined
with melphalan 9 mg/m2 for 4 days and prednisone
60 mg/m2 for 4 days every 42 days (MPV arm) com-
pared to melphalan and prednisone alone (MP arm)
[18]. The median age of the group was 71 years. Un-
favorable cytogenetics had no adverse impact on out-
come. The overall response rate was 82% in the
MPV arm and 50% in the MP arm. Complete or
near-complete response was 35% in the MPV arm,
but only 5% in the MP arm. The 2-year OS was
83% in the MPV arm versus 70% in the MP arm,
with respective median time to progression of 24
months versus 17 months. These findings led to the
FDA’s 2008 approval of bortezomib for initial combi-
nation therapy for newly diagnosed MM. Although
grade 3-4 peripheral neuropathy was reported in
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75% of cases. The MPV regimen was superior to
the MP regimen in terms of time to progression,
time to next therapy, PFS, OS, and complete response
rate [18].
Another study compared melphalan-prednisone-
thalidomide (MPT) and melphalan-prednisone (MP)
in patients with MM over age 75 years (median age,
78.5 years) [19]. The thalidomide dose was 100 mg/
day. The MPT arm demonstrated significantly better
OS and PFS. Despite the fact that 77% of the MP
group received thalidomide as salvage therapy, this
did not eliminate the survival advantage conferred by
the use of thalidomide as initial therapy in the MPT
arm [19]. The median OS was 45 months in the
MPT arm versus 28 months in the MP arm. The rate
of peripheral neuropathy grade 2-4 was 20% in the
MPT arm and 5% in the MP arm.
Aphase I-II trial ofmelphalan-prednisone-lenalido-
mide was reported in elderly patients withMM (median
age, 70years). At the completionof thephase I study, the
optimal dosage schedule was determined to be lenalido-
mide 10 mg/day and melphalan 0.18 mg/kg/day for 4
days every 4 to 6 weeks for a maximum of 9 cycles
[20]. At a median of 7 cycles, CR was 24%, VGPR was
29%, and partial remission was 33%. In a historical
comparison, lenalidomide-melphalan-prednisone pro-
duced an overall response rate of 85%, compared with
76% for melphalan-prednisone-thalidomide and only
48% for melphalan-prednisone. Moreover, like borte-
zomib, lenalidomide appears to be capable of overcom-
ing the poor prognosis conferred by del(13q) and t(4;14)
in MM [21].
Lenalidomide is excreted renally and requires dos-
age modification in patients with renal failure. Current
recommendations suggest a maximum lenalidomide
dose of 10 mg/day in patients with a creatinine clear-
ance of 30 to 50 mg/min,; 15 mg every 48 hours in pa-
tients with a creatinine clearance of\30 mg/min, and
15 mg 3 times a week after each dialysis treatment in
those with end-stage renal disease [22]. Bortezomib re-
quires no dose modification for renal failure and has
been successfully administered in full dosages with
no significantly increased toxicity [23].
In conclusion, the addition of novel agents to
standard therapies, either melphalan- or high-dose
dexamethasone–based, has been found to improve re-
sponse rates, PFS, and OS. The addition of high-dose
therapy results in higher complete response and very
good partial response rates after induction with novel
agents. These novel agents appear to overcome the
adverse prognosis associated with unfavorable cytoge-
netics. For newly diagnosed patients, lower-intensity
dexamethasone therapy produces higher 12- and
24-month OS. Combining immunomodulatory drugs
(IMIDs) and proteasome inhibitors is feasible and canresult in higher complete and near-complete response
rates.AUTOLOGOUS ANDALLOGENEIC STEM
CELLTRANSPLANTATION IN MULTIPLE
MYELOMA
Autologous Stem Cell Transplantation
The introduction of high-dose melphalan therapy
supported by autologous transplantation of peripheral
hematopoietic stem cells (ASCTs) was the first im-
provement inMM treatment after 3 decades of stagna-
tion. ASCT is currently considered the standard of
care in patients with MM under age 65 years and with-
out renal failure, and MM is the leading indication for
ASCTworldwide. This situation is the consequence of
2 randomized trials performed in the 1990s demon-
strating the superiority of ASCT over conventional
chemotherapy in terms of response rate, PFS, and
OS [24]. The benefit from ASCT was related to
more effective tumor burden reduction, and a signifi-
cant relationship with CR or at least VGPR was
demonstrated. The findings of subsequent randomized
studies were not as positive, however; although CR
rate and PFS were almost always increased with
ASCT, OS was not [24]. This was attributed in part
to the use of ASCT at relapse in the conventional che-
motherapy arms; therefore, ASCT did improve OS,
but its optimal timing remained a matter of debate.
Further dosage intensification was then explored
with the objective of increasing theCR rate. Three ran-
domized studies found that double ASCTwas superior
to single ASCT in terms of PFS, but only 1 study found
an advantage in terms of OS [24]. The only factor pre-
dicting the impact of the secondASCTwas the result of
the first ASCT; only patients achieving less thanVGPR
after the first ASCT had a better outcome after under-
going a second ASCT. Drawing definite conclusions
from this study is complicated by the fact that this sub-
analysis had not been planned initially and may have
been underpowered [24].
Moreover, patients with poor-risk MM, defined by
a high b2-microglobulin level plus poor-risk cytoge-
netic abnormalities like t(4;14) or del(17p), still had
a poor outcome despite undergoing 2 ASCTs. Clearly,
new approach were needed, at least for these patients.
Moreover, the role of double ASCT should be reeval-
uated in the context of new available therapies.
The introduction of novel agents (thalidomide,
bortezomib, and lenalidomide) was the next step.
The first advance was the use of thalidomide in main-
tenance treatment after ASCT. Three randomized
studies showed that thalidomide after ASCT improves
the CR/VGPR rate, PFS, and OS [24]; however, 2
questions remain:
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 What are the optimal dose and duration of thalido-
mide maintenance?
Prolonged treatment increases the risk of neuro-
logic toxicity and possibly of resistance. Lenalidomide,
which is better tolerated in long-term use, appears to
be a logical maintenance treatment and is currently un-
der evaluation in randomized trials. Novel agents have
been studied as induction therapy before ASCT, with
the objective of further increasing the CR/VGPR
rate. The thalidomide-dexamethasone combination
was found to induce better response than dexametha-
sone alone or in combination with vincristine and
doxorubicin (in the vincristine doxorubicin dexameth-
asone [VAD] regimen); however, 4 cycles of this com-
bination did not appear to increase the CR/VGPR rate
either before or after high-dose melphalan therapy
[24]. Three-drug combinations (plus doxorubicin or
cyclophosphamide) appear to be more effective
(VGPR of 49% and 67%, respectively) [25,26]. A large
Intergroupe Francophone du Myelome (IFM) ran-
domized study found that bortezomib plus dexameth-
asone increased the CR/VGPR rate compared with
VAD both before ASCT (44% vs 19%) and after
ASCT (63% vs 44%) [27] and could become a new
standard or the backbone of more complex combina-
tions (with the addition of doxorubicin, cyclophospha-
mide, or thalidomide).
These 3-drug bortezomib-based combinations are
currently undergoing testing in randomized trials.
Preliminary results of an Italian trial have shown
a WGPR rate of up to 77% after ASCT with 3 cycles
of VTD as induction treatment [28]. Thus, with the
use of novel agents before ASCT, high CR/VGPR
rates can be achieved both before and after ASCT,
and although the follow-up remains short, this im-
proved tumor burden reduction hopefully will trans-
late into longer PFS.
Finally, these novel agents can be used both before
and after ASCT. A number of randomized trials are
currently evaluating this approach. Some results
from an Arkansas group have been made available; in
the Total Therapy 2 program, all patients received
a complex program including tandem ASCT and
were randomly allocated to receive or not receive tha-
lidomide throughout treatment. The thalidomide arm
has demonstrated significantly superior 5-year PFS
(56% vs 45%) [29]. The same group recently reported
preliminary results from the Total Therapy 3 pro-
gram, in which bortezomib was added in induction
and consolidation/maintenance to the thalidomide
arm of the previous protocol. The findings to date
are impressive, with 2-year PFS of 84% and OS of
87% [30].
Some other trials including novel agents without
ASCT have yielded outstanding results as well [31-33].A series of randomized trials have compared the classi-
cal MP combination with MP plus a novel agent—
thalidomide (MPT), bortezomib (MPV), and, more
recently, lenalidomide (MPR)—in elderly patients.
The findings demonstrate not only that the novel
agent–containing regimens are clearly superior to MP
in terms of response rate, including CR and PFS, but
also that CR/VGPR rates and median PFS are quite
comparable to those achieved with single ASCT
(40% to 45% and 24 to 28 months, respectively),
even with an older study population.
Trials with lenalidomide-dexamethasone are more
recent and the follow-up is too short to allow definite
conclusions; nonetheless, the preliminary results are
impressive, particularly with lower doses of dexameth-
asone, which are better tolerated. Long-term treat-
ment with lenalidomide-dexamethasone or with a
3-drug combination including bortezomib have
yielded very high CR/VGPR rates (approximately
70%) [34,35]. Short-term OS rates also are unprece-
dentedly high [36]. Although these studies of lenalido-
mide-dexamethasone are still premature and often
mix older patients and younger patients undergoing
ASCT, this approach without upfront ASCT appears
to be very attractive. Further randomized studies
comparing novel agents with or without ASCT are
planned.Allogeneic Stem Cell Transplantation
Although myeloablative allogeneic (allo) SCTmay
be the only curative treatment for MM (because it in-
duces molecular remissions and plateau of the PFS
curves), it has been almost completely abandoned be-
cause of its high transplantation-related mortality
rate, up to 50% in even front-line therapy [37]. The
current approach is to reduce the tumor burden with
high-dose melphalan plus ASCT and to use the
graft-versus-myeloma effect of lymphoid donor cells
with reduced-intensity conditioning (RIC) allo SCT.
Three prospective studies have been published [38-
40]. Their results differ, which can be attributed to
differences in selection criteria and conditioning
regimens. Whereas the Italian study showed the
superiority of tandem ASCT–RIC allo SCT over dou-
ble ASCT, the results of the IFM study in poor-risk
patients failed to show a benefit of RIC allo SCT
[41]. Although RIC allo SCT is much better tolerated
than myeloablative allo SCT, it still carries a 10% to
15% rate of 1-year transplantation-related mortality
and a 30% to 40% rate of chronic graft-versus-host
disease [42]. Considering the good results achieved
with novel agents with or without ASCT, RIC allo
SCT probably should not be offered to good-risk
MM patients and should be proposed to other patients
only in prospective clinical trials.
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